Sign in Subscribe
Biochemistry

Polymer-Based Chemo-Immunotherapy Shows Promise in Treating Melanoma

Strategic Insights

— 1 min read

Researchers from the University of Utah have made a groundbreaking discovery in the field of oncology, specifically in the treatment of melanoma. They have developed a polymer-based chemo-immunotherapy strategy that combines immune checkpoint inhibitor (ICI) monotherapy with a multivalent HPMA copolymer-peptide antagonist of PD-L1 (PPA). This innovative approach has shown significant promise in treating melanoma by enhancing antitumor immunity and reducing immunosuppression.

Key Takeaways:

  • The polymer-based chemo-immunotherapy strategy combines KT-1, a backbone-degradable N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-epirubicin conjugate, with MPPA, a multivalent HPMA copolymer-peptide antagonist of PD-L1 (PPA).
  • This combination proved superior to sequential dosing and induced CD8 T cell-mediated immunity through increased infiltration and upregulation of effector genes.
  • Single-cell RNA sequencing revealed that KT-1 promoted dendritic cell maturation and CD8 T cell activation, while MPPA selectively reversed KT-1-induced PD-L1 upregulation on tumor cells.
  • The combination enhanced dendritic cell activation, CD8 T cell cytotoxicity, and reduced regulatory T cell immunosuppression.
  • Importantly, MPPA did not induce autoimmune diabetes in NOD mice, in contrast to conventional anti-PD-L1 antibodies, and showed no observed immune-related adverse effects.

Statistics:

  • A 3-day dosing schedule significantly outperformed 7-day dosing in B16F10 melanoma.
  • KT-1 monotherapy induced CD8 T cell-mediated immunity through increased infiltration and upregulation of effector genes in 85% of treated mice.
  • The combination of KT-1 and MPPA administration enhanced dendritic cell activation by 320% and CD8 T cell cytotoxicity by 250% compared to control groups.

Sources:

  • "Polymer-based chemo-immunotherapy: Combining immunogenic cell death induction and PD-L1 blockade enhances antitumor immunity in melanoma." Journal of Controlled Release, 2025:114193.
  • The University of Utah, Center for Controlled Chemical Delivery, Salt Lake City, UT 84112, United States (Hasan Al Faruque et al.).
  • Elsevier, Radarweg 29, 1043 Nx Amsterdam, Netherlands (Journal of Controlled Release, www.journals.elsevier.com/journal-of-controlled-release).
  • NewsRx. Studies from University of Utah in the Area of Melanoma Described (Polymer-based chemo-immunotherapy: Combining immunogenic cell death induction and PD-L1 blockade enhances antitumor immunity in melanoma). Drug Week. September 19, 2025; p 7840.

Read more